AtriCure, Inc.

WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
CUSIP

04963C209
SEDOL

B0C8KV2
CIK

0001323885

www.atricure.com
LEI:
FIGI: BBG000BL6CB5
ATRC

AtriCure, Inc.
GICS: - · Sektor: Healthcare · Sub-Sektor: Medical Instruments & Supplies
AI
PROFILER
NAME
AtriCure, Inc.
ISIN
US04963C2098
TICKER
ATRC
MIC
XNAS
REUTERS
ATRC.OQ
BLOOMBERG
ATRC US
GIF DE 728x90
FÜR INVESTOREN
FÜR TRADER
Börsenhandel Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Mi., 20.11.2024       AtriCure
US04963C2098

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Piper Sandler 36th Annual Healthcare Conference. AtriCure’s management is schedu...
Do., 07.11.2024       AtriCure
US04963C2098

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Stifel 2024 Healthcare Conference. AtriCure’s management is scheduled to particip...
Di., 29.10.2024       AtriCure
US04963C2098

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2024 financial results. “Our broad-based growth in the third quarter reflects strong, ongoing adoption trends throughout ou...
Mo., 28.10.2024       AtriCure
US04963C2098

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming UBS Global Healthcare Conference. AtriCure’s management is scheduled to participa...
Di., 15.10.2024       AtriCure
US04963C2098

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE MAX™ cryoablation probe. The cryoSPHERE MAX probe features a larger ball tip designed to optimize Cry...
Di., 08.10.2024       AtriCure
US04963C2098

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2024 financial results on Tuesday, October 29, 2024. AtriCure will host an audio webcast at 4:30 ...
Di., 01.10.2024       AtriCure
US04963C2098

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received regulatory approval to sell the EnCompass® Clamp in CE-marked countries in the European Union, and European surgeons...
Di., 27.08.2024       AtriCure
US04963C2098

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the first patient was treated with the AtriClip® FLEX-Mini™ device, which recently received 510(k) clearance. The AtriClip FLEX-Mini...
Do., 22.08.2024       AtriCure
US04963C2098

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received an expanded indication for the AtriClip® in CE-marked countries in Europe. The product is now indicated for use in p...
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Informationen zu Product Placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S